none
Conditions
Interventions
Group A: aminolevulinic acid administration group
Administration method: Subjects take 2 capsules per day, which contains 50 mg 5-aminolevulinic acid phosphate and 29 mg ferrous citrate
Administration
Sponsors
Kinouchi Kenichiro
Ito Hiroshi
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male aged >= 20 and < 80 years 2. Subjects whose grip power in better side is 26-40kg 3. Subjects who provide written consent form to participate in this study by their own free will after full explanation of the study
Exclusion criteria
Exclusion criteria: 1. Subjects with history of hypersensitivity against aminolevulinic acid, or those who meet the contraindication for aminolevulinic acid 2. Subjects with diabetes mellitus whose HbA1c is >= 9.0%, or subjects with chronic kidney disease whose eGFR is < 30 3. Subjects with uncontrolled psychiatric disorder 4. Subjects who cannot provide written consent form, who cannot understand the outline and purpose of the study, or who need legal representatives 5. Subjects who are considered to be unsuitable for participation by attending physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of handgrip from baseline to week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Chang e of following items from baseline to week 12 1. lower limb muscle strength (knee extension muscle strength) 2. walking speed (5m walking time) 3. 5 times sit to stand test (SS-5) 4. muscle mass (bioelectrical impedance analysis) 5. fat mass (bioelectrical impedance analysis) 6. lower leg circumference (at max circumference) 7. body weight 8. HbA1c 9. high sensitivity CRP (hsCRP) | — |
Contacts
Public ContactKazutoshi Miyashita
Keio University Hospital
Outcome results
None listed